Estimates_of_radiation_absorbed_dose_for_intraperitoneally_administered_iodine-131_radiolabeled_B72.3_monoclonal_antibody_in_patients_with_peritoneal_carcinomatoses._Using_a_newly_available_model_for_determining_estimates_of_radiation_absorbed_dose_of_radioisotopes_administered_intraperitoneally,_we_have_calculated_absorbed_dose_to_tumor_and_normal_tissues_based_on_a_surgically_controlled_study_of_radiolabeled_antibody_distribution._Ten_patients_with_peritoneal_carcinomatosis_received_intraperitoneal_injections_of_the_murine_monoclonal_antibody_B72.3_radiolabeled_with_131I._Biodistribution_studies_were_performed_using_nuclear_medicine_methods_until_laparotomy_at_4-14_days_after_injection._Surgical_biopsies_of_normal_tissues_and_tumor_were_obtained._The_marrow_was_predicted_to_be_the_critical_organ,_with_maximum_tolerated_dose_200_rad_(2_Gy)_to_marrow_expected_at_about_200_mCi_(7.4_GBq)._In_patients_with_large_intraperitoneal_tumor_deposits,_the_tumor_itself_is_an_important_source_tissue_for_radiation_exposure_to_normal_tissues._Local_"hot-spots"_for_tumor-absorbed_dose_were_observed,_with_maximum_tumor-absorbed_dose_calculated_at_11,000_rad_(11_Gy)_per_100_mCi_(3.7_GBq)_administered_intraperitoneal;_however,_tumor_rad_dose_varied_considerably._This_may_pose_serious_problems_for_curative_therapy,_especially_in_patients_with_large_tumor_burdens.